ワクチン製造委託の世界市場2016-2026

◆英語タイトル:Vaccine Contract Manufacturing Market Report 2016-2026 : Leading Countries, Technologies and Companies
◆商品コード:VGAIN5122112
◆発行会社(調査会社):visiongain
◆発行日:2015年12月
◆ページ数:148
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥242,865見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥404,865見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥674,865見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、ワクチン製造委託の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・ワクチンのヒストリー
・ワクチン製造技術動向
・世界のワクチン製造市場、市場規模
・世界のワクチン製造委託市場、市場規模
・主要地域分析
・世界のワクチン製造動向
・主要企業分析
・結論
【レポートの概要】

What can be expected from the vaccine contract manufacturing market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 148-page report provides 76 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analysis and commercial developments.

See revenue forecasts for the leading international markets
How will leading national markets perform to 2026? Our study forecasts revenues in national markets including products, including:
• US
• Germany
• France
• Italy
• Spain
• UK
• Japan
• China
• Brazil
• Russia
• India

Leading companies and potential for market growth
Overall revenue for the vaccine contract manufacturing market will reach $1047.3m in 2019, our work forecasts. We predict good revenue growth through to 2026. Increasing demands for therapeutic vaccines and an ageing population will help drive the market for vaccines over the forecast period, which in turn helps drive the vaccine contract manufacturing business.

Our work analyses the key companies in the market. See visiongain’s analysis of leading companies, including these:
• Baxter BioPharma Solutions
• Boehringer Ingelheim
• Catalent
• Charles River Laboratories
• IDT Biologika
• Lonza
• Meridian Life Science
• Sigma Aldrich Fine Chemical (Merck)
• Synco Bio Partners

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Company news relevant to the market

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect Vaccine contract manufacturing industry?
Our new report discusses issues and events affecting the vaccine contract manufacturing market. You will find discussions, including qualitative analyses:
• The emergence of developing markets as manufacturing centres
• Increasing potential in both established and emerging markets

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

【レポートの目次】

1. Report Overview
1.1 World Vaccine Contract Manufacturing Market Highlights
1.2 Why You Should Read This Report?
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
1.10 Exchange Rates

2. Introduction to Vaccines
2.1 The History of Vaccines
2.2 How Do Vaccines Work?
2.2.1 Artificial Immunity
2.3 Types of Vaccine
2.3.1 Live, Attenuated Vaccines (LAVs)
2.3.2 Recombinant Live Vaccines
2.3.3 Inactivated Vaccines
2.3.4 Toxoid Vaccines
2.3.5 Subunit Vaccines
2.3.6 Conjugate Vaccines
2.3.7 Recombinant Subunit Vaccines
2.3.8 DNA Vaccines
2.3.9 Recombinant Vector Vaccines
2.3.10 Therapeutic Vaccines
2.4 Diseases Preventable with Vaccines
2.5 The Rise of the Vaccines Market
2.6 Technological and Regulatory Improvements

3. Vaccine Manufacturing Technologies, 2015
3.1 Summary of Vaccine Technology Trends
3.2 New Substrates for Vaccine Production
3.2.1 Shift towards Cell-Based Manufacturing Technology
3.2.2 Benefits of Cell-Based Techniques
3.2.3 Mammalian Cell Lines
3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.2.3.2 Vero Cells
3.2.3.3 PerC6 Cells
3.2.4 Avian-Derived Cell Lines
3.2.4.1 EB66 Stem Cell Technology: Vivalis
3.2.5 Plant-Based Vaccines
3.2.5.1 Medicago’s Proficia VLP Vaccine Technology
3.2.6 Insect Egg-Based Production Systems
3.2.6.1 Novavax
3.2.6.2 Protein Sciences Corporation (PSC)
3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.3.1 AdVac Technology: Crucell
3.3.2 AdCEV Vectors: AfriVax
3.3.3 Pfenex Expression Technology: Pfenex
3.4 Equipment Trends
3.4.1 The Shift Towards Disposable Single-use Equipment
3.4.2 Bioreactors and Vaccine Production
3.4.2.1 Single-Use Bioreactors
3.4.2.2 Main Applications of Disposable Bioreactors
3.4.2.3 Current Single-Use Bioreactor Systems on the Market
3.5 Prefilled Syringes and Vaccines
3.5.1 Growing Market for Pre-Filled Syringes
3.5.2 Pre-Filled Vaccine Products 2015
3.5.3 Drivers and Restraints for Pre-Filled Syringes
3.5.4 Product Stability and Quality Assurance Programme
3.5.4.1 Paediatric H1N1 Vaccine
3.5.4.2 Reported Challenges Flu Vaccines
3.5.4.3 Novartis’ Agriflu and Fluad Ban is Lifted
3.5.4.4 Baxter Flu Vaccine and Side Effects
3.5.4.5 Reported Shelf Life With H1N1 Vaccine
3.6 Lyophilisation and Vaccine Manufacturing
3.6.1 Lyophilisation of Vaccines will Increase
3.7 Cell Media Can Improve Virus Yield

4. The Global Vaccine Manufacturing Market 2016-2026
4.1 Overview of the Global Vaccine Manufacturing Market 2016-2026
4.2 World Vaccine Market Forecast 2016-2026
4.3 The Global Vaccine Market By Submarket, 2014 and 2015
4.4 Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
4.5 Paediatric Vaccines Market Overview
4.6 Adult Prophylactic Vaccines Market Overview
4.7 Influenza Vaccines Market Overview
4.8 Therapeutic Vaccines Market Overview

5. The Global Vaccine Contract Manufacturing 2016-2026
5.1 Outsourcing in the Pharmaceutical and Biotechnology Industry
5.1.1 Reasons to Outsource
5.1.2 Benefits of Outsourcing
5.1.3 The Challenges in Outsourcing Vaccine Manufacturing
5.1.4 Why Should Companies Outsource Vaccine Manufacturing?
5.1.5 Strategic Outsourcing vs. Tactical Outsourcing
5.1.6 Virtual Companies
5.2 Contract Manufacturing Organisations (CMOs)
5.2.1 Manufacturing Services Offered by CMOs
5.2.2 Vaccine Manufacturing Activities Typically Outsourced
5.3 The Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast 2016-2026
5.4 Contract Manufacturing Market for Vaccines 2016-2026
5.4.1 Market Size for Contract Manufacturing of Vaccines 2014
5.4.2 Vaccine Contract Manufacturing Market Forecast 2016-2026

6. The Leading National Markets for Vaccine Contract Manufacturing, 2016-2026
6.1 The Leading National Markets for Vaccine Contract Manufacturing
6.2 The Leading National Markets for Vaccine Contract Manufacturing, 2014-2016
6.3 The Leading National Markets for Vaccine Contract Manufacturing, 2016-2026
6.3.1 The US Vaccine Contract Manufacturing Market Forecast, 2016-2026
6.3.2 The EU5 Vaccine Contract Manufacturing Market, 2014 and 2015
6.3.2.1 The EU5 Vaccine Contract Manufacturing Market, 2016-2026
6.3.2.2 The German Vaccine Contract Manufacturing Market, 2016-2026
6.3.2.3 The Italian Vaccine Contract Manufacturing Market, 2016-2026
6.3.2.4 The UK Vaccine Contract Manufacturing Market, 2016-2026
6.3.2.5 The French Vaccine Contract Manufacturing Market, 2016-2026
6.3.2.6 The Spanish Vaccine Contract Manufacturing Market, 2016-2026
6.3.3 The Japanese Vaccine Contract Manufacturing Market, 2016-2026
6.3.4 The Chinese Vaccine Contract Manufacturing Market, 2016-2026
6.3.4 The Indian Vaccine Contract Manufacturing Market, 2016-2026
6.3.5 The Russian Vaccine Contract Manufacturing Market, 2016-2026
6.3.6 The Brazilian Vaccine Contract Manufacturing Market, 2016-2026

7. Leading Vaccine Contract Manufacturing Companies, 2016-2026
7.1 Leading Vaccine Contract Manufacturing Organisations
7.2 Baxter BioPharma Solutions
7.3 Boehringer Ingelheim
7.3.1 Recent Financial Performance
7.3.2 Ben Venue Laboratories
7.3.3 Manufacturing Deals 2011-2015
7.4 Catalent
7.4.1 Recent Financial Performance
7.4.2 Catalent: Financial Performance by Segment, 2011-2015
7.4.3 Catalent Injectable Vaccines
7.4.4 Catalent: Zydis Technology
7.4.5 Regional Market Expansion Strategy
7.5 Charles River Laboratories
7.5.1 Recent Financial Performance, 2011-2014
7.5.2 Financial Performance by Segment, 2010-2015
7.5.3 Recent Financial Performance, 2015
7.5.4 Vaccine Manufacturing Services
7.5.5 Charles River Avian Vaccine Services
7.5.6 Vaccine Manufacturing Expansion
7.5.7 Outlook and Early Stage Restructuring
7.5.8 Partnerships
7.5.8.1 Partnership with AstraZeneca
7.5.8.2 Partnership with Batavia
7.6 IDT Biologika GmbH
7.7 Lonza
7.7.1 Recent Financial Performance
7.7.2 Financial Performance in H1 2015
7.7.3 Manufacturing Division Restructuring
7.8 Meridian Life Science
7.8.1 Recent Financial Performance, 2010-2014
7.8.2 Recent Financial Performance by Segment, 2011-2014
7.8.3 Current Developments, 2015
7.9 Sigma-Aldrich Fine Chemicals (SAFC) (Merck KGaA)
7.10 SynCo Bio Partners
7.11.1 Recent Developments
7.11.1.1 Expansion of Facilities
7.11.1.2 FDA Approval of Partner Application

8. Vaccine Manufacturing Market: World Market Trends 2016-2026
8.1 Vaccine Contract Manufacturing Industry Trends
8.2 Strengths
8.2.1 Many Companies Cannot Afford In-house Capabilities
8.2.2 Outsourcing Improves Time to Market
8.2.3 Manufacturers Get Access to Specialised Technologies
8.2.4 Shift Towards Emerging Markets as Favourable Outsourcing Destinations
8.3 Weaknesses
8.3.1 Mass Vaccine Manufacturing Kept In-house
8.3.2 A Highly Fragmented Vaccine Contract Manufacturing Market
8.3.3 An Unpredictable Supply and Demand Business Model
8.4 Opportunities
8.4.1 Many Vaccines in the Product Pipeline
8.4.2 Emerging Market’s Growing Demand for Vaccines
8.4.2.1 Dynamic Change: Emerging Markets are Major Vaccine Developers
8.4.3 Changing World Demographics
8.5 Threats
8.5.1 Post Recession: Biotech Suffer from Severe Cuts in Capital Funding
8.5.2 The Public are Slow to Accept Novel Technologies
8.5.3 Perception of Risk by the Original Vaccine Manufacturers

9. Conclusion
9.1 Overview
9.2 Regulatory and Quality Standards Create High Barriers of Entry
9.3 Emerging Markets Will Show Stronger Growth

10. Glossary

List of Tables
Table 1.1 Currency Exchange Rates, 2014
Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD – Present
Table 3.1 Vaccine Development Pipeline Using Crucell’s AdVac Technology, 2015
Table 3.2 Benefits and Drawbacks of Using Disposable Technology for Vaccine Production, 2015
Table 3.3 Companies Providing Disposable Biomanufacturing Platforms/Systems, 2015
Table 3.4 Some Leading Pre-Filled Syringe Vaccine Products, 2015
Table 3.5 Prominent Lyophilised Vaccines, 2015
Table 3.6 Examples of Serum-Free Media for Vaccine Manufacturing, 2015
Table 4.1 The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2014-2026
Table 4.2 The Global Vaccine Market: Revenue ($bn) and Market Share by Submarket (%), 2014-2015
Table 5.1 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.1 The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m) and Market Share (%), 2014-2015
Table 6.2 The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.3 The Leading National Vaccine Contract Manufacturing Markets Forecast: Market Shares (%), 2016 and 2026
Table 6.4 The US Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.5 The EU5 National Vaccine Contract Manufacturing Markets: Revenue ($m) and Market Share (%) by Country, 2014-2015
Table 6.6 The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.7 The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.8 The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.9 The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.10 The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.11 The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.12 The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.13 The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.14 The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.15 The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 6.16 The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Table 7.1 Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2010-2014
Table 7.2 Catalent: Revenue($m) and AGR (%), 2010-2015
Table 7.3 Catalent by Segment: Revenue($m), AGR (%), and Intersegment Revenue Eliminations, 2011-2015
Table 7.4 Charles River Laboratories: Revenue ($bn) and AGR (%), 2010-2014
Table 7.5 Charles River Laboratories: Newly Revised Reportable Segments
Table 7.6 Charles River Laboratories: Revenue ($bn) by Segment, 2010-2012
Table 7.7 Charles River Laboratories: Revenue ($bn) by Segment, 2013-2014
Table 7.8 Charles River Laboratories: Quarterly Revenue ($m) by Segment, 2015
Table 7.9 Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities, 2015
Table 7.10 Lonza Custom Manufacturing: Revenue ($m) and AGR (%), 2010-2014
Table 7.11 Meridian Bioscience: Revenue ($m), AGR (%), 2010-2014
Table 7.12 Meridian Bioscience: Revenue ($m) and AGR (%) by Segment, 2011-2014
Table 7.13 SynCo Bio Partners Capabilities 2015
Table 8.1 SWOT Analysis of the Vaccine Contract Manufacturing Market, 2016-2026

List of Figures
Figure 3.1 Influenza Vaccine Production Using a Cell-Based Manufacturing Method, 2015
Figure 3.2 Medicago’s Product Pipeline, 2015
Figure 3.3 Novavax’ Insect Egg-Based Vaccine Production Process, 2015
Figure 3.4 Pre-filled Syringes Market: Drivers and Restraints, 2015-2026
Figure 4.1 The Global Vaccine Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
Figure 4.2 The Global Vaccine Market: Market Share by Submarket (%), 2015
Figure 5.1 Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry, 2015
Figure 5.2 The Global Pharmaceutical Contract Manufacturing Forecast: Revenue ($bn), 2014, 2020 and 2026
Figure 5.3 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 6.1 The Leading National Vaccine Contract Manufacturing Markets: Market Share (%) by Region, 2015
Figure 6.2 The US Vaccine Contract Manufacturing Forecast: Revenue ($m) and AGR (%),2014-2026
Figure 6.3 The EU5 Vaccine Contract Manufacturing Markets: Market Share (%) by Country, 2015
Figure 6.4 The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 6.5 The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 6.6 The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 6.7 The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 6.8 The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 6.9 The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 6.10 The Japanese Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Figure 6.11 The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%) 2014-2026
Figure 6.12 The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%) 2014-2026
Figure 6.13 The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 6.14 The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 7.1 Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2010-2014
Figure 7.2 Catalent: Revenue ($m) and AGR (%), 2010-2015
Figure 7.3 Catalent: Revenue ($m) by Segment, 2011-2015
Figure 7.4 Catalent: Marker Shares (%) by Segment, 2015
Figure 7.5 Charles River Laboratories: Revenue ($bn) and AGR (%), 2010-2014
Figure 7.6 Charles River Laboratories: Quarterly Revenue ($m) by Segment, 2014-2015
Figure 7.7 Lonza Custom Manufacturing: Revenue ($m )and AGR (%), 2010-2014
Figure 7.8 Meridian Bioscience: Revenue ($m), andAGR (%), 2010-2014
Figure 7.9 Meridian Bioscience: Revenue ($m) by Segment, 2011-2014
Figure 7.10 Meridian Bioscience: Market Share (%) by Segment,2014
Figure 8.1 Drivers and Restraints for the Vaccine Contract Manufacturing Sector, 2016-2026
Figure 9.1 Vaccine & Vaccine Contract Manufacturing Market: AGR(%), 2015-2026

【レポートのキーワード】

ワクチン製造委託、ワクチン製造技術、医薬品製造受託企業

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[ワクチン製造委託の世界市場2016-2026]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年09月26日現在 207,216 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆